额外的领域A含有纤维素的肺高血压和功能阻断抗体的治疗效果
Isabell Singerer1,2, Laura Tempel1, Katja Gruen1
1Department of Internal Medicine I, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany.
额外的域A含有纤维素 (ED-A+Fn) 在肺高血压 (PH) 的发展中起着关键作用. 在小鼠模型中,用抗体阻止ED-A+Fn显著改善了PH症状并减少了组织损伤.
科学领域:
- 心血管研究研究心血管研究
- 肺部医学 肺部医学
- 免疫学 免疫学 免疫学
背景情况:
- 肺高血压 (PH) 涉及复杂的血管和右心室 (RV) 重建.
- 额外的域A含有纤维素 (ED-A+Fn) 参与PH的发病.
研究的目的:
- 研究ED-A+Fn在PH发展中的功能作用.
- 在PH模型中评估针对ED-A+Fn的基于抗体的治疗策略.
主要方法:
- 对ED-A+Fn淘汰赛 (KO) 和野生型 (WT) 小鼠在单氨酸 (MCT) 诱导的PH的比较.
- 在PH模型中给予抗ED-A+Fn抗体 (F8) 或控制抗体 (KSF).
- 在Sugen 5416/低氧诱导的PH模型中验证.
主要成果:
- 带有MCT诱导PH的WT小鼠显示RV缩压升高和RV功能受损.
- 与WT相比,具有PH的KO小鼠表现出明显较少的组织损伤.
- 在WT PH小鼠中,F8抗体治疗改善了血液动力学和心声学参数,并减少了肺组织损伤.
- 在Sugen 5416/低氧模型中,F8治疗证明了疗效.
结论:
- ED-A+Fn对于PH的发病过程至关重要,并且是一个可行的治疗点.
- 抗体介导的ED-A+Fn阻断可以减弱和部分逆转PH相关的组织重塑.
更多相关视频
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
09:23Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
